Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.
Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.
Has no product on sale since it withdrew Relyvrio, its ALS drug, so it earns no product revenue and lives on cash from that drug's earlier sales. Its spending now goes to avexitide, a drug aimed at dangerously low blood sugar after weight-loss surgery.
Moat: none (IP / patents). Lost its only approved product; must re-prove itself with a new pipeline.
Headquarters: Cambridge, Massachusetts, US · Founded: 2019 · Employees: 136
Size Amylyx Pharmaceuticals (AMLX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 1446th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.62 on 18 Nov 2026.
Performance Over six months the shares gained 92.8%, against +3.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 100.0% over the last twelve months (peer median +3.6%).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $87.4M | $381M | $22.2M |
| Revenue growth | — | -100% | -77% | +1,613% | — |
| Gross profit | -$282,000 | -$525,000 | -$38.2M | $354M | $18.8M |
| EBITDA | -$175M | -$153M | -$255M | $39.9M | -$201M |
| Net income | -$163M | -$145M | -$302M | $49.3M | -$198M |
| Free cash flow | -$130M | -$123M | -$168M | $10.7M | -$182M |
| Capital expenditure | $4.14M | $138,000 | $36.4M | $1.24M | $2.53M |
| Total debt | $4.94M | $5.96M | $1.98M | $4.24M | $6.28M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX | $3.42B | +93% | +100% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | $2.16B | -30% | -50% | 46% | 0.4× | n/a |
| Rezolute RZLT | $411M | +32% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMLX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.5% | +2.9% | 4th lowest of 21 |
| 6-month return | +92.8% | +3.4% | 2nd highest of 20 |
| Distance from 52-week high | -16.5% | -22.7% | 10th highest of 21 |
| Revenue growth (TTM) | +100.0% | +3.6% | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | 8.1× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 0.3× | -10.0% | +5.4% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 2.2× | -7.5% | -9.6% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |